Safety Profile of IBD Therapeutics: Infectious Risks

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been associated with an elevated risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.

Original languageEnglish (US)
Pages (from-to)691-709
Number of pages19
JournalGastroenterology Clinics of North America
Volume38
Issue number4
DOIs
StatePublished - Dec 2009

Fingerprint

Inflammatory Bowel Diseases
Opportunistic Infections
Safety
Immunologic Factors
Therapeutics
Histoplasmosis
Biological Factors
Adrenal Cortex Hormones
Tuberculosis
Tumor Necrosis Factor-alpha

Keywords

  • Anti-tumor necrosis factor
  • Corticosteroids
  • Immunomodulator
  • Infection
  • Inflammatory bowel disease

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Safety Profile of IBD Therapeutics : Infectious Risks. / Afif, Waqqas; Loftus, Jr, Edward Vincent.

In: Gastroenterology Clinics of North America, Vol. 38, No. 4, 12.2009, p. 691-709.

Research output: Contribution to journalReview article

@article{24d5bb5b9aa949ba98ad016e459ef53e,
title = "Safety Profile of IBD Therapeutics: Infectious Risks",
abstract = "Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been associated with an elevated risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.",
keywords = "Anti-tumor necrosis factor, Corticosteroids, Immunomodulator, Infection, Inflammatory bowel disease",
author = "Waqqas Afif and {Loftus, Jr}, {Edward Vincent}",
year = "2009",
month = "12",
doi = "10.1016/j.gtc.2009.07.005",
language = "English (US)",
volume = "38",
pages = "691--709",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Safety Profile of IBD Therapeutics

T2 - Infectious Risks

AU - Afif, Waqqas

AU - Loftus, Jr, Edward Vincent

PY - 2009/12

Y1 - 2009/12

N2 - Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been associated with an elevated risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.

AB - Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been associated with an elevated risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.

KW - Anti-tumor necrosis factor

KW - Corticosteroids

KW - Immunomodulator

KW - Infection

KW - Inflammatory bowel disease

UR - http://www.scopus.com/inward/record.url?scp=70350776816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350776816&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2009.07.005

DO - 10.1016/j.gtc.2009.07.005

M3 - Review article

C2 - 19913209

AN - SCOPUS:70350776816

VL - 38

SP - 691

EP - 709

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 4

ER -